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ABSTRACT
Introduction: Cigarette smoking continues to be the
leading cause of preventable death and is the main risk
factor of major diseases such as chronic obstructive
pulmonary disease (COPD). The best treatment to help
smokers quit is a combination of behavioural support
with pharmacotherapy. Varenicline is the newest drug
on the market and has been shown to be effective in
the general smoking population and in smokers with
COPD. The safety profile of varenicline was initially
established using standard approaches to
pharmacovigilance, but postmarketing reports have
raised concerns about a possible association between
the use of varenicline and cardiovascular and
neuropsychiatric events. Although recent studies have
not confirmed such an association, further research is
needed given the large number of smokers who are
being prescribed varenicline, including important
subgroups such as smokers with COPD who may be
particularly vulnerable to side effects of drugs. The aim
of this study is to assess the cardiovascular and
neuropsychiatric safety of varenicline using data from
the QResearch general practice (GP) database.
Methods and analysis: We will conduct a
retrospective cohort study in the QResearch GP
database. Patients will be categorised into three
exposure groups: prescription of (1) varenicline,
(2) bupropion or (3) nicotine replacement therapy
(NRT Rx; =reference group). We will separately
consider major incident neuropsychiatric and
cardiovascular outcomes that occur during 6 months
of follow-up using Cox proportional hazards models,
adjusted for confounders. Furthermore, propensity
score analysis will be used as an analytical approach to
account for potential confounding by indication.
Ethics and dissemination: This work involves
analysis of anonymised, routinely collected data.
The protocol has been independently peer-reviewed by
the QResearch Scientific Board and meets the
requirements of the Trent research ethics committee.
We plan to disseminate the results from this study via
articles in international peer-reviewed journals and
presentations at relevant national and international
health conferences.
INTRODUCTION
Cigarette smoking continues to be the leading
cause of preventable death, killing nearly six
million people worldwide each year.1 Smokers
who do not stop lose at least one decade of life
expectancy.2 Chronic obstructive pulmonary
Strengths and limitations of this study
▪ The proposed study uses routinely collected data
from a general practice database. The large sample
size will allow the investigation of rare adverse
events that may be associated with medication
usage.
▪ Unrestricted inclusion of all patients from a very
large general practice population will mean that
findings from this study will be highly generalis-
ability to other populations.
▪ As we are using an observational study design and
treatment allocation is non-randomised, bias in the
form of confounding by indication will be present.
We will therefore use different statistical techniques
such as propensity scores to adjust our findings
for the most important confounders.
▪ A disadvantage of using routinely collected general
practices is that some variables of potential interest
may be missing and/or of poor quality.
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disease (COPD) is one of the major causes of death in
smokers and mortality rates are still increasing.2 3 The
WHO estimates that about 3.3 million people die from
COPD worldwide each year and this ﬁgure is expected to
rise substantially in the coming decades.4
It has been estimated that at least 80% of COPD cases
could be avoided by the eradication of cigarette smoking.5
Smoking cessation is therefore the ﬁrst and most import-
ant intervention in patients with COPD as it is the only
intervention that effectively slows down the accelerated
decline in lung function.6 Furthermore, smoking cessation
reduces symptoms of cough and sputum, improves health
status and reduces exacerbations of COPD.7 Patients with
COPD therefore have a greater and more urgent need to
stop smoking than smokers without this disease.8 Yet, the
proportion of current smokers is higher among people
with COPD than in the general population.9 In England,
for example, more than one-third of patients with COPD
still smoke.10
The best treatment to help smokers quit smoking accord-
ing to UK and international clinical guidelines is a combin-
ation of pharmacotherapy and behavioural support.8 11
Effective pharmacotherapies are bupropion, nicotine
replacement therapy (NRT; delivered, eg, through nicotine
gum or patch) and varenicline. Varenicline, a selective
α4β2 nicotine acetylcholine receptor partial agonist, is the
newest drug on the market; it was introduced in the UK in
December 2006 and has been recommended by the
National Institute of Health and Care Excellence (NICE)
as a treatment option since July 2007.12
Varenicline has been shown in experimental studies to
be more effective than bupropion and nicotine patches
in promoting smoking cessation in the general smoking
population.13 14 Furthermore, varenicline is the only
drug with proven long-term efﬁcacy in smokers with
COPD; a recent trial showed a fourfold increase in con-
tinuous abstinence over a period of 12 months in users
of varenicline compared with placebo.15 Other medica-
tions have failed to prove efﬁcacy over a period longer
than 6 months in this group of smokers.16 Varenicline
has thus become the most frequently prescribed
smoking cessation medication after NRT in England.17
The safety proﬁle of varenicline was initially established
using standard approaches to pharmacovigilance.
However, subsequent postmarketing reports have raised
concerns about the safety of varenicline with regard to
cardiovascular and neuropsychiatric events. For example,
one meta-analysis reported a small, but signiﬁcantly
increased risk of serious adverse cardiovascular events in
users of varenicline.18 Possible mechanisms for an
increased cardiovascular risk may relate to varenicline’s
action on α3β4 receptors in the peripheral ganglia and
subsequent release of acetylcholine, release of catechola-
mines and the central inﬂuence of α4β2 and α7 receptors
on blood pressure homoeostasis.19 A possible mechanism
for an increased neuropsychiatric risk may in part be
explained by smoking itself, that is, by neuropsychiatric
conditions that already existed prior to the quit attempt
or other smoking-related conditions that are themselves
associated with an increased neuropsychiatric risk.20 21
Nevertheless, the European Medicines Agency and the
US Food and Drug Administration issued warnings that
serious neuropsychiatric symptoms had occurred in
smokers trying to stop with varenicline including changes
in behaviour, agitation, depressed mood, suicidal idea-
tion, and attempted and completed suicides.22 23
Many recent studies conducted outside of clinical
trials in the general smoking population did not,
however, ﬁnd any increased risk of cardiovascular and
neuropsychiatric events in varenicline users24–31 (see
table 1 for an overview of previous studies). Further
research is needed given the large number of smokers
around the globe who wish to stop smoking and who are
being prescribed varenicline. There is also a need to
assess its safety in important subgroups of the smoking
population—in particular smokers with COPD who may
be eminently vulnerable for side effects of drugs
because they are at increased risk of comorbidity, includ-
ing cardiovascular and neuropsychiatric diseases.6 32
Randomised controlled trials and even meta-analyses
are often underpowered to detect rare, serious adverse
events.33 Large general practice (GP) databases, which
routinely collect data on prescribed treatments and
disease outcomes are an alternative, promising approach
to investigate rare events. An advantage of large GP data-
bases is the higher generalisability of ﬁndings compared
with randomised controlled trials where patients need to
provide informed consent for participation and where
selection of patients occurs through exclusion criteria,
resulting in a population which is healthier and less vul-
nerable than the general population. A disadvantage of
most GP databases is that analyses are restricted to rou-
tinely collected data (and may therefore be incomplete
and/or inaccurate). Even more important, analyses of
these non-randomised data may be biased because of
confounding by indication, that is, the fact that smokers
who self-select to use a particular smoking cessation
medication differ from patients not using this medica-
tion with regard to the factors that have an effect on the
outcome. For example, it has been shown that smokers
who use pharmacotherapy are heavier and more severely
addicted smokers than those who try to quit without
pharmacotherapy.34–36 To reduce this bias in the current
context, adverse events in patients using varenicline
need to be compared with patients using other drugs
with the indication smoking cessation, such as bupro-
pion or NRT on prescription (Rx). In addition, statistical
adjustment for confounders is important. Previous
studies successfully used GP databases to assess the safety
of smoking cessation medications (see table 1) and the
methodology used therein can inform new studies.
The aim of this study is to assess the safety of vareni-
cline using data from the QResearch GP database. Our
primary research question is: in smoking patients from
general practice, is the use of varenicline for smoking
cessation compared with bupropion and NRT Rx
2 Kotz D, et al. BMJ Open 2014;4:e005281. doi:10.1136/bmjopen-2014-005281
Open Access
Table 1 Overview of previous studies on cardiovascular and neuropsychiatric events in users of varenicline and bupropion
Author (year
of publication) Study type Exposure Outcome
Incidence of
events per 1000
patients per year
Relative event rates*
(95% CIs)
Svanström
(2012)29
Retrospective cohort study
using national patient
registry
Varenicline vs.
bupropion
Cardiovascular event (acute coronary syndrome,
ischaemic stroke, or cardiovascular death)
Varenicline: 6.9,
bupropion: 7.1
HR=0.96 (0.67 to 1.39)
Acute coronary syndrome Varenicline: 4.7,
bupropion: 3.9
HR=1.20 (0.75 to 1.91)
Ischaemic stroke Varenicline: 1.9,
bupropion: 2.5
HR=0.77 (0.40 to 1.48)
Cardiovascular death Varenicline: 0.4,
bupropion: 0.7
HR=0.51 (0.13 to 2.02)
Prochaska
(2012)26
Meta-analysis of 14
randomised controlled trials
Varenicline vs. placebo Cardiovascular serious adverse event (myocardial
infarction, unstable angina, coronary
revascularisation, coronary artery disease,
arrhythmias, transient ischaemic attacks, stroke,
sudden death or cardiovascular-related death, or
congestive heart failure)
Not reported RR=1.40 (0.82 to 2.39)
Singh (2011)18 Meta-analysis of 14
randomised controlled trials
Varenicline vs. placebo Cardiovascular event (ischemia, arrhythmia,
congestive heart failure, sudden death or
cardiovascular-related death)
Varenicline: 10.6,
placebo: 8.2
OR=1.72 (1.09 to 2.71)
Thomas
(2013)28
Retrospective cohort study
using GP database
Varenicline vs NRT
Bupropion vs. NRT
Fatal or non-fatal self-harm Varenicline: 2.6,
bupropion: 2.5,
NRT: 3.6
HR=0.88 (0.52 to 1.49)
HR=0.83 (0.30 to 2.31)
Varenicline vs NRT
Bupropion vs NRT
Treated depression Varenicline: 57.5,
bupropion: 41.6,
NRT: 77.5
HR=0.75 (0.65 to 0.87)
HR=0.63 (0.46 to 0.87)
Pasternak
(2013)27
Retrospective cohort study
using national patient
registry
Psychiatric adverse event (emergency
department visit or in-patient admission with a
psychiatric diagnosis)
Not reported HR=0.85 (0.55 to 1.30)
Meyer (2013)31 Retrospective cohort study
using a military health
system claims database
Varenicline vs. NRT ICD-9 coded diagnosis of schizophrenia,
non-organic psychoses, suicide attempt, or
drug-induced/transient mental-, mood-,
delusional-, anxiety-, personality-, post-traumatic-
or depressive disorders.
Varenicline: 18.1,
NRT: 15.8
HR=1.14 (0.56 to 2.34)
Buggy (2013)30 Retrospective cohort study
in patients who received a
prescription of varenicline by
their GP
Varenicline
(without comparison)
GP-reported depression, anxiety, aggression,
suicidal ideation, and non-fatal self-harm during
three months since prescription of varenicline
NA NA. The hazard during the
observation period was
constant for all events
except for anxiety
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associated with an increased risk of cardiovascular and/
or neuropsychiatric events? This research question will
also be addressed in the subgroup of smokers with
COPD.
METHODS AND ANALYSIS
We will conduct a retrospective cohort study involving all
adult patients from QResearch who used varenicline,
bupropion, or an NRT Rx between 1 January 2007 and
31 December 2012. QResearch is a very large, validated
electronic GP database; it includes data from the anon-
ymised health records of over 13 million patients from
753 general practices from across England that use the
EMIS software system (http://www.qresearch.org).
QResearch has been used for various research studies,
including studies of the incidence and risk neuropsychi-
atric and cardiovascular events 37–41 (for a complete and
up-to-date list of studies visit: http://www.qresearch.org/
SitePages/publications.aspx). External validation studies
showed that studies using this database yield similar
results as those using other databases such as the Clinical
Practice Research Datalink (CPRD)42 43 and The Health
Improvement Network (THIN) database.44 Several spe-
ciﬁc methods described in this protocol are based on the
methods used in previous studies on the association
between varenicline and neuropsychiatric events which
used CPRD,24 28 because this database is similar to
QResearch (for a detailed comparison see, eg, refs. 42
and 43). Hence, we will use methods which have been
established by other researchers in the current context.
Furthermore, we will be able to compare some of the
results from our study with the previous studies using
CPRD.
Inclusion and exclusion criteria
Only patients meeting all of the following criteria will be
included:
▸ Registered for >12 months prior to data extraction at
any time during the study period, including those
who die or de-register during their study period.
▸ Prescription of either varenicline alone, bupropion
alone, or NRT Rx alone between 1 January 2007 and
30 June 2012. The date of ﬁrst prescription of one of
these drugs will deﬁne the individuals entry date to
the cohort. We chose this start date because vareni-
cline was introduced to the UK market in December
2006. The end date will be the latest date of data
extraction from the database. The latest date of a
patient to be included will be 30 June 2012 in order
to have 6-month follow-up data until the end of the
study period (31 December 2012).
▸ Aged 18–100 years. We will include only patients over
the age of 18 because varenicline and bupropion are
only licensed for use in adults in the UK.
Patients with one or more of the following criteria will
be excluded:
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▸ Patients with less than 1 year of QResearch records
before their ﬁrst recorded prescription to ensure that
data are of adequate quality.
▸ Temporary residents.
▸ Use of one of the three smoking cessation drugs
during 12 months prior to the start date of the study
(ie, in the period from 1 January 2006 to 31
December 2006) to assure an adequate washout
period, so that any adverse events are not attributable
to the previous use of these drugs.
▸ Prescription of a combination of smoking cessation
drugs or prescription of another smoking cessation
drug during the 6-month follow-up after the patient’s
entry date to single out adverse events of the three
distinct drugs.
The analysis in the subgroup of smokers with COPD
will be restricted to patients aged 35 years and over at
their individual entry date, with a recorded diagnosis of
COPD and recordings of spirometry and Medical
Research Council (MRC) dyspnoea score45 at any time
(all recordings based on appropriated Read codes; see
online supplementary appendix). We chose 35 years as
the lower age limit for inclusion because COPD is
usually not diagnosed before that age. The MRC scale
is used as a COPD indicator in the UK National Health
Service Quality Outcomes Framework and measures
self-perceived disability caused by breathlessness and
distinguishes between ﬁve levels of severity.45 The score
will be used in our analyses as an indicator of disease
severity.
Exposure measures
Patients will be categorised into three exposure groups:
(1) varenicline alone, (2) bupropion alone or (3) NRT
Rx alone (=reference group: any form of NRT, such as
nicotine patch, inhaler, nasal spray, gum, sublingual
tablet or lozenge), based on the drug they were ﬁrst
prescribed. In the UK, all three drugs are only licensed
for use to aid smoking cessation (as described and
assessed in a previous study using a different GP data-
base28). The exposure category will be deﬁned by this
initial drug and patients will be considered exposed to
the respective drug and no others. Thus, all patients
included in the cohort will be unique. The usual
course of treatment is 12 weeks of varenicline, 9 weeks
for bupropion and 8–12 weeks for NRT Rx. Start of
follow-up will begin for each patient on the date of the
ﬁrst prescription of the smoking cessation medication
(which is also the patient’s entry date to the cohort)
and will end after 6-month follow-up or when reaching
the speciﬁc outcome of interest (ie, a major neuro-
psychiatric and/or cardiovascular event). Patients who
were lost to follow-up because they left the practice or
died will be censored on that date. The duration of
6-month follow-up is based on the suggestion that
adverse events from drug use may occur after the treat-
ment is ﬁnished.
Outcome measures
We will consider separate major incident neuropsychi-
atric and cardiovascular outcomes that occur during
6 months of follow-up (based on appropriate Read codes;
see online supplementary appendix) for which a poten-
tial association with varenicline use has been sug-
gested.18 24 25 As a secondary outcome, we will assess the
occurrence of these events during 3 months of follow-up.
Neuropsychiatric outcomes include: (1) fatal or non-fatal
intentional self-harm and (2) depressive disorder.
Cardiovascular outcomes include: (1) ischaemic heart
disease (including myocardial infarction and angina);
(2) cerebral infarction and haemorrhage; (3) heart
failure; (4) peripheral vascular disease and (5) cardiac
arrhythmia (including cardiac arrest). Recordings of
these neuropsychiatric and cardiovascular events prior to
the patient’s entry date to the cohort will be considered
to account for confounding by indication.
Confounding factors
Confounding by indication is an important potential
source of bias in a safety analysis using observational (ie,
non-randomised) data. This form of confounding means
that patients who are prescribed a certain treatment may
differ in prognostic factors from patients who are pre-
scribed a different treatment or who do not receive any
treatment. In the current context, for example, patients
using medication for smoking cessation (varenicline or
bupropion) may differ from patients who try to stop
smoking without medication. They may have been more
exposed to tobacco and are therefore more at risk of
cardiovascular events. In the current study, we will ﬁrst
of all reduce the risk of confounding by indication by
comparing users of varenicline or bupropion with users
of NRT Rx.
Given that concerns have been raised about vareni-
cline adverse events, it is possible that patients with a
history of cardiovascular or neuropsychiatric disease or
risk factors may be less likely to be prescribed vareni-
cline. Similarly, bupropion is contra-indicated in certain
patient subgroups and there is a caution against pre-
scribing in others. Therefore, an extensive list of
patient-level and practice-level characteristics will be
considered for inclusion as potential confounders in
the analyses. These include the following variables
measure at or prior to the patient’s entry date to the
cohort: age, sex, Townsend index of multiple depriv-
ation,46 Strategic Health Authority of the GP practice,
relevant comorbidities from the Charlson Index47
(ie, COPD, diabetes, peptic ulcer disease, renal disease,
rheumatological disease or cancer) and alcohol misuse.
For the subgroup analysis in smokers with COPD only,
we also added MRC dyspnoea score as a marker for
COPD severity. As previously mentioned, any recordings
of the neuropsychiatric and cardiovascular diseases that
occurred prior to the patient’s entry date to the cohort
will also be considered.
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Sample size calculation
We will consider HRs of 1.5 or higher as clinically mean-
ingful, indicating a 50% or higher increased risk of cardio-
vascular or neuropsychiatric events in users of varenicline
compared with NRT Rx. The sample size calculation is
based on detecting such an HR in stroke, as previous
research showed this to be the outcome with the lowest
incidence rate (see table 1). A query of the QResearch
database showed an incidence rate of 2/1000 person-years
in the general patient population. For the 6-month
follow-up period, we will therefore, assume hazard rates of
0.001 and 0.0015 for the NRT Rx and varenicline groups,
respectively. Furthermore, the calculation should take into
account a higher prevalence of NRT Rx usage than vareni-
cline. A recent study using the English Clinical Practice
Research Datalink (CPRD) reported a ratio of 2.6:1 for
NRT Rx versus varenicline.28 Therefore, using the method
by Freedman48 for computing the power of the log-rank
test, we ﬁnd that the required number of NRT Rx and var-
enicline users should be 128 798 and 49 538, respectively,
to achieve 80% power to obtain a signiﬁcant result at
α=0.05 (two-tailed).
It should be noted that the sample size for the current
study will be given by the actual number of patients from
the QResearch database who received a prescription of
either varenicline, bupropion or NRT Rx during our study
period. Once we have received the data set and know
these numbers, we can re-compute the statistical power of
all seven events under the above assumptions.
Statistical analyses
We will compare baseline differences of potential con-
founding factors between the three exposure groups
(varenicline, bupropion and NRT Rx). Kaplan-Meier
survival curves will be generated and examined for the
three groups. We will then use Cox proportional hazards
regression models to assess the association between
medication use and each of the above mentioned main
outcomes, adjusted for the aforementioned confound-
ing factors. The exposure group factor will ﬁrst be tested
with a likelihood ratio test (based on two degrees of
freedom). In addition, we will report HRs with 95% CIs,
with days since start of the treatment as the time scale.
HRs will be calculated for varenicline and bupropion
with NRT Rx as a reference. The proportional hazards
assumption will be assessed by a χ2 test for the inter-
action between treatment status and the underlying time
scale. Start of the follow-up will begin for each patient
on the date of the ﬁrst prescription of the smoking ces-
sation medication and will end after 6-month follow-up
or when reaching the speciﬁc outcome of interest.
Patients will be censored who died during follow-up,
who left their practice, or reached the end of the
follow-up period.
In an explorative analyses we will assess whether the
risk of cardiovascular and neuropsychiatric events differ
according to sex, by testing the interaction terms in the
Cox models between medication use and sex. In case of
signiﬁcant and clinically relevant differences, results will
be reported separately for males and females.
We will use propensity score analysis49 as an additional
analytic approach to account for potential confounding
by indication. In multiple logistic regression models
medication use (with varenicline vs NRT Rx as depend-
ent variable in the ﬁrst model and bupropion vs NRT
Rx in the second model) will be regressed on the afore-
mentioned potential confounders. The resulting pre-
dicted probability values for medication use (possible
range 0.0–1.0) will be used as propensity score for using
one drug versus the other. In order to estimate how
much of the variation in medication use can be
explained by the potential confounders, we will calculate
the area under the receiver operating characteristics
curve. The possible value from this analysis will be
between 0.5 (indicating no association between the pro-
pensity score and medication use) and 1.0 (indicating
that medication use can be completely explained by the
propensity score). We will then trim the sample by
excluding patients with a propensity score correspond-
ing with the 2.5th centile or lower in the varenicline,
respectively bupropion group and by excluding patients
with a propensity score corresponding with the 97.5th
centile or higher in the NRT Rx group. This trimming is
intended to exclude patients from the subsequent ana-
lyses which used a form of medication strongly contrary
to expectation (eg, a patient who had most of the
characteristics associated with the use of varenicline but
who used NRT Rx) and may therefore reduce residual
confounding.50 In the propensity score analyses we will
then match patients using varenicline to patients using
NRT Rx in a ﬁxed 1:1 ratio by using the nearest neigh-
bour algorithm51 (MatchIt package in R52). Likewise, we
will match bupropion users with NRT Rx users. In these
two matched samples, we will again use Cox propor-
tional hazards regression models to assess the association
between medication use and each of the above men-
tioned main outcomes. HRs will be calculated for vareni-
cline and bupropion with NRT Rx as a reference.
Another approach we will consider to account for
potential confounding by indication is an instrumental
variable analysis.53 An instrumental variable is assumed
to resemble the tossing of a coin to assign patients to a
treatment in randomised controlled trials. As such, it
provides a method to obtain an unbiased estimate of the
association between medication use and adverse events
in the current study. A pre-requisite is to ﬁnd a valid and
strong instrumental variable, which is often difﬁcult,
because this variable must fulﬁl the following criteria:
(1) it must be a predictor of the treatment (in our case
the use of varenicline, bupropion or NRT Rx); (2) it
must not be directly related to the outcome (cardiovas-
cular or neuropsychiatric events) except through the
effect of the treatment and (3) it must not be associated
with measured or unmeasured confounders. We will
therefore explore variables that fulﬁl the above criteria.
A potential instrumental variable is the physician’s
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prescribing preference, which is often used in prescrip-
tion drug research with observational data.54
All analyses will be repeated for the secondary
outcome (ie, the occurrence of neuropsychiatric and
cardiovascular events during 3 months of follow-up) and
in the subgroup of smokers with COPD.
Data will be analysed with complete cases, that is,
patients with missing data on one of the variables age, sex,
Townsend index, Strategic Health Authority of the GP
practice will be excluded. Only in the subgroup analyses of
patients with COPD, those patients with COPD with
missing data on spirometry or the MRC dyspnoea score
will also be excluded. The percentage missing data for
these variables will be reported. Data on recorded diseases
that occurred prior to a patient’s entry date to the cohort
and which will be used as potential confounders will be
coded as ‘1’ if the disease occurred or otherwise ‘0’: dia-
betes, peptic ulcer disease, renal disease, rheumatological
disease, cancer, alcohol misuse, and the neuropsychiatric
and cardiovascular diseases of outcome.
All analyses will be undertaken in R (V.3.0.2 or later).
Codes used in R will be reported as supplementary
material of publications. All statistical tests will be two-
sided with p<0.05 indicating signiﬁcance.
ETHICS AND DISSEMINATION
This protocol has been independently peer-reviewed by
the QResearch Scientiﬁc Board and meets the require-
ments of the Trent research ethics committee. Two articles
are planned to be submitted to international peer-
reviewed journals: (1) results from the general smoking
population and (2) results from the subgroup analysis in
smokers with COPD. The reporting will be in accordance
with the Strengthening the Reporting of Observational
Studies in Epidemiology (STROBE) criteria.55 The R-code
from the data analyses will be published as supplementary
material. The ﬁndings from these articles are planned to
be presented at relevant national and international health-
care/academic conferences.
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